PROS1 and infection: Mutations in the SARS-CoV-2 S protein, especially at positions 346 and 444, mainly R346T and K444T, increased during the autumn of 2022 (Figure 4a), indicating an increase in infections that were resistant to mAb treatment with tixagevimab and cilgavimab.